Project Grant K23AI182453
Award Date
8/19/24
Completion Date
7/31/29
Dollars Obligated
$195K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This federal Project Grant award, valued at $243,361.00 and running from August 15, 2024 to July 31, 2026, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant is funding a project by Rush University Medical Center in Chicago, Illinois to establish workflows for rapid and inexpensive whole genome sequencing (WGS) of Neisseria gonorrhoeae (NG) directly from urine, throat, and rectal...
This $429,244 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a power-free, PCR-level molecular diagnostic device to detect Chlamydia trachomatis and Neisseria gonorrhoeae from self-collected vaginal swabs. The project will utilize a proprietary amplification chemistry and prototype microfluidic device design to create an easy-to-use, accurate, and accessible...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Quarksen LLC provides funding to develop an affordable, point-of-care diagnostic device for detecting viral and non-viral sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, HIV, hepatitis C, and trichomoniasis. The project aims to create a device with an array of sensors that can rapidly and accurately detect STI biomarkers from cervical...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $233,250 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to the University of Washington to develop and validate a rapid, point-of-care molecular test to detect Treponema pallidum antibiotic resistance. The key products to be delivered under this 2-year grant include: A multiplexed, point-of-care allele-specific loop-mediated isothermal amplification (AS-LAMP) assay to detect genetic markers of...
This $884,453 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a rapid, point-of-care hepatitis C virus (HCV) detection test using a novel signal amplification technology. The award to Brigham & Women's Hospital, a prominent academic medical center in Boston, MA, will fund research to create a cost-effective, sensitive, and specific HCV antigen test...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,999 to Planet Biotechnology Incorporated to develop a novel bispecific antibody for the prevention of gonorrhea. The project aims to engineer a fusion protein that combines elements of human antibodies with immune system components to broadly neutralize the causative bacteria, Neisseria gonorrhoeae, including...
This $499,151 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a novel diagnostic test for syphilis infection. The project aims to create an immuno-PCR diagnostic platform that can detect unique peptidoglycan fragments shed by the syphilis-causing bacterium, Treponema pallidum, in order to provide early-stage diagnosis of the disease. This...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Baebies, Inc. to develop a rapid, point-of-care diagnostic test to identify viable sexually transmitted infections (STIs). The goal is to create a fully automated, CLIA-waived diagnostic platform that can detect and differentiate viable STI pathogens, such as Chlamydia trachomatis and Neisseria gonorrhoeae,...
This federal Project Grant award of $466,500.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to develop rapid and ultrasensitive aptamer-based detection technologies for the diagnosis of Treponema pallidum infections, the causative agent of syphilis. The key products and services to be delivered through this funding include: 1) Developing aptamers that strongly and specifically bind to T....
This $1,413,007 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support the development and evaluation of the CRISPR-TB diagnostic tool for detecting tuberculosis (TB) in children under 5 years old. The University of Washington is the primary grantee and will lead a large prospective study of 400 children with suspected TB. The project aims to expand upon prior successful...